Why Palantir Stock Plummeted Last Month But Is Soaring in July

Palantir stock fell through June on AI-software sell-offs and renewed concerns over a non-renewal of its UK NHS contract (last valued at ~$440M, expiring early next year), but has rebounded ~11% in July. Catalysts include DA Davidson upgrading the shares to Buy and lifting the 1-year price target from $165 to $175, plus an expanded Palantir–Nvidia partnership integrating Nemotron AI models into its stack for U.S. and allied government customers. Additional upside came from Michael Burry trimming/reducing his Palantir short position after previously reaffirming a short bet.

Analysis

The tradeable signal here is mostly positioning, not a step-change in fundamentals. The market is still treating AI software as the crowded, lower-conviction leg of the AI trade, so PLTR can rebound sharply when sentiment improves even if underlying revenue math barely changes. The NHS overhang looks more like a headline multiple-risk than a revenue existential, which means the first-order hit can be larger than the eventual cash-flow impact.

Second-order, the real winner from the recent product integration may be NVDA more than PLTR, because it reinforces the idea that its stack is becoming the default plumbing for enterprise and government AI deployment. But that also cuts both ways: if investors keep preferring semis, PLTR’s rerating can stall even on decent execution. The competitive risk is less one rival and more model commoditization—if large-model vendors or systems integrators bundle similar workflows at lower perceived switching costs, PLTR’s premium multiple becomes harder to defend.

Catalyst timing is important. Over days to weeks, this can stay a momentum/name-recognition trade driven by analyst upgrades and short-covering; over 1-3 months, the NHS decision path is the real event risk; over 6-18 months, it comes down to whether government deployments expand enough to offset any lost contract and prove recurring platform value. The contrarian view is that consensus may be overestimating the importance of a single public-sector renewal and underestimating how much of PLTR’s rerating depends on investors shifting from semiconductor scarcity to software monetization.

Key Decisions for Investors

• Tactically buy PLTR on pullbacks over the next 2-4 weeks; prefer a call spread or defined-risk long rather than outright size. Risk/reward is attractive only if the July rebound holds and the stock does not roll over back into the late-June tape.
• Pair trade idea: long PLTR / short NVDA for 1-3 months as a relative-value bet that software sentiment can outperform crowded AI hardware. This is a high-beta pair, so cut the short if NVDA reasserts leadership on any strong data-center print or guidance beat.
• Set an event alert around the NHS renewal path; if renewal is explicitly extended, add to PLTR into the confirmation squeeze. If the contract is lost and management does not offset it with stronger commercial/government pipeline commentary, fade the bounce.
• No clean trade in MU from this note; treat it as a read-through on AI capital rotation rather than a company-specific catalyst.